- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01582516
Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
A Phase I/II Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma
In the Netherlands a 2 center investigator-driven phase I/II clinical trial is initiated in June 2010 testing the oncolytic adenovirus Delta24-RGD to treat glioblastoma patients. The virus is administrated using convection-enhanced delivery by 4 catheters as delivery technique, targeting solid tumor as well as infiltrated tumor cells within the peri-tumoral brain. Patients will be enrolled in cohorts of 3 per dose-level. The dose levels to be explored are: 10^7, 10^8, 10^9, 10^10, 3*10^10 and 10^11 viral particles (vp). Once the MTD has been determined, or the study has reached the highest dose cohort, a further 6 or 9 patients will be enrolled at the MTD and evaluated for safety and preliminary signs of efficacy, such that in total at least 12 patients have received the MTD.
The primary objective is to determine the safety and tolerability of Delta-24-RGD administered by CED to the tumor and the surrounding infiltrated brain in patients with recurrent GBM. Secondary objectives are to determine the Progression Free Survival (PFS), Overall Survival (OS), and tumor response rate in patients with recurring tumors amenable for surgical resection and treated at the MTD.
Cerebrospinal fluid as well as brain interstitial fluid by microdialysis next to the routinely collected samples of blood at various timepoints before, during and after virus infusion. Various neurodegenerative biomarkers as well as markers of immune response will be assessed in these samples.
Furthermore extensive sampling and PCR analyses will be performed to evaluate distribution and shedding of the virus.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Rotterdam, Netherlands
- Erasmus Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically proven primary Glioblastoma Multiforme (GBM) will be eligible for this protocol.
- Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan within 3 weeks prior to registration after failing prior resection (surgery or biopsy) and/ or chemo- and/or radiation therapy.
Recurring tumors must either be accessible for surgery, or , when not accessible for surgery meet the following criteria:
- unifocal
- midline shift < 0.5 cm
- no radiological signs of uncal herniation
- All recurring tumors must be restricted to one hemisphere, without signs of subependymal spreading.
- Before start of virus treatment histological analysis of the resected, or biopsied tumor recurrence must confirm the diagnosis of GBM (based on frozen section).
- Patients may or may not have had prior chemotherapy.
- Patients must be able to read and understand the informed consent document and must sign and date the informed consent. Procedures to obtain such informed consent should be according to ICH-GCP, the local regulatory requirement and the rules followed at the institute.
- Patients must be > 18 and < 75 years old.
- Patients must have a Karnofsky performance status rating > 70 (Appendix 2).
- Patients must have recovered from the toxic effects of prior therapy. For example, they must be at least two weeks after vincristine, 6 weeks after nitrosoureas, 3 weeks after procarbazine or temozolomide administration, and 6 weeks after radiation therapy.
- If sexually active, patients must be willing to use barrier contraception for the duration of the study.
Patients must have adequate hepatic, renal and bone marrow function, defined as
- absolute neutrophil count (ANC) > 1,5* 109/L
- platelet count of > 100* 109/L
- ALT (SGPT), AST (SGOT) and Alkaline Phosphatase < 2 times ULN
- total bilirubin <1.5 mg/dL
- creatinine <1.5 times ULN
- urea (BUN) <1.5 times ULN
Exclusion Criteria:
- Patients with active uncontrolled infection. Upper pulmonary infection and flu-like signs or presence of adenovirus in pre-operative throat-swab or serum sample as determined by PCR. All patients must be afebrile (<38.0 C) at the start of therapy
- Evidence of bleeding diathesis or use of anticoagulant medication.
- Patients with systemic diseases or other unstable conditions which may be associated with unacceptable anesthetic/ operative risk and/or which would not allow safe completion of this study protocol, e.g. uncontrolled seizures.
- Because of the potential risk of a recombinant virus containing a gene involved in cellular growth regulation and differentiation which could potentially affect a developing fetus or growing infant, females who are pregnant, at risk of pregnancy, or breast feeding a baby during the study period are excluded.
- Because of the potential risk of serious infection in immune-compromised individuals, patients known to have HIV infection are excluded.
- Patients with a known germline deficit in the retinoblastoma gene or its related pathways.
- Patients with other primary malignancy than GBM. However, patients with curatively treated carcinoma-in situ or basal cell carcinoma or patients who have been disease free for at least 2 years and not using any anti-cancer therapy, are eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Delta24-RGD
Intracerebral slow continuous infusion of study drug in increasing dose
|
slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
treatment related serious adverse events
Time Frame: untill 3 months after treatment
|
untill 3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of participants alive after 6 months and after 1 year : Progression free survival after 6 months and overall survival after 6 months and one year.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Clemens Dirven, MD PhD, Erasmus Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioblastoma
- Brain Neoplasms
- Adenoviridae Infections
Other Study ID Numbers
- NL24958.000.08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Tumor
-
University of California, San FranciscoGilead SciencesSuspendedBrain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, PediatricUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Technical University of MunichRecruiting
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
-
GT Medical Technologies, Inc.RecruitingBrain Tumor | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor - Metastatic | Brain Tumor, Adult: Glioblastoma | Brain Tumor, Adult MeningiomaUnited States
-
The Hospital for Sick ChildrenPediatric Oncology Group of OntarioCompletedChildhood Brain TumorCanada
-
Ohio State University Comprehensive Cancer CenterCompletedAdult Brain TumorUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
Clinical Trials on delta-24-RGD adenovirus
-
DNAtrix, Inc.CompletedCentral Nervous System Diseases | Brain CancerUnited States
-
DNAtrix, Inc.Merck Sharp & Dohme LLCCompletedNervous System Diseases | Glioma | Glioblastoma | Neuroectodermal Tumors | Brain Cancer | Gliosarcoma | Brain Neoplasm | Malignant Brain Tumor | Neoplasm, Neuroepithelial | Neoplasm by Histologic Type | Neoplasm, Nerve TissueUnited States, Canada
-
M.D. Anderson Cancer CenterDNAtrix, Inc.RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | IDH1 wt AlleleUnited States
-
Clinica Universidad de Navarra, Universidad de...DNAtrix, Inc.; Alcyone Lifesciences, Inc.CompletedNeoadjuvant Therapy | Brainstem GliomaSpain
-
Washington University School of MedicineWithdrawn
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 RearrangementsUnited States
-
Seventh Medical Center of PLA General HospitalActive, not recruiting